{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:23:31Z","timestamp":1793917411348,"version":"4.8.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K23AG59888"],"award-info":[{"award-number":["K23AG59888"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s13311-023-01405-0","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T11:30:05Z","timestamp":1690284605000},"page":"914-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"title":["Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update"],"prefix":"10.1016","volume":"20","author":[{"given":"Golnaz","family":"Yadollahikhales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-646X","authenticated-orcid":false,"given":"Julio C.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1007\/s13311-023-01405-0_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\u201d","volume":"8","author":"Alzheimer","year":"1995","journal-title":"Clin Anat"},{"issue":"Pt 4","key":"10.1007\/s13311-023-01405-0_bib2","first-page":"1102","article-title":"Oskar Fischer and the study of dementia","volume":"132","author":"Goedert","year":"2009","journal-title":"Brain"},{"issue":"22","key":"10.1007\/s13311-023-01405-0_bib3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1212\/WNL.0000000000007583","article-title":"A brief history of \u201cAlzheimer disease\u201d: Multiple meanings separated by a common name","volume":"92","author":"Knopman","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01405-0_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1192\/bjp.110.465.146","article-title":"Old age mental disorders in newcastle upon tyne. I. A study of prevalence","volume":"110","author":"Kay","year":"1964","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1007\/s13311-023-01405-0_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-023-01405-0_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12149-018-1292-6","article-title":"SPECT and PET imaging in Alzheimer's disease","volume":"32","author":"Valotassiou","year":"2018","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1007\/s13311-023-01405-0_bib7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-022-05999-z","article-title":"PET molecular imaging for pathophysiological visualization in Alzheimer's disease","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/CON.0000000000001248","article-title":"Neuroimaging in dementia","volume":"29","author":"Risacher","year":"2023","journal-title":"Continuum"},{"issue":"5054","key":"10.1007\/s13311-023-01405-0_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"6","key":"10.1007\/s13311-023-01405-0_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1007\/s13311-023-01405-0_bib11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The evolution of preclinical Alzheimer's disease: implications for prevention trials","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1007\/s13311-023-01405-0_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/14737175.2018.1531706","article-title":"BACE inhibitors in clinical development for the treatment of Alzheimer's disease","volume":"18","author":"Panza","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-023-01405-0_bib14","article-title":"The therapeutic and diagnostic potential of amyloid beta oligomers selective antibodies to treat Alzheimer's disease","volume":"15","author":"Viola","year":"2021","journal-title":"Front Neurosci"},{"issue":"9","key":"10.1007\/s13311-023-01405-0_bib15","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","article-title":"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A\u03b2 oligomers","volume":"29","author":"De Felice","year":"2008","journal-title":"Neurobiol Aging"},{"issue":"8","key":"10.1007\/s13311-023-01405-0_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nn1503","article-title":"Regulation of NMDA receptor trafficking by amyloid-\u03b2","volume":"8","author":"Snyder","year":"2005","journal-title":"Nat Neurosci"},{"issue":"14","key":"10.1007\/s13311-023-01405-0_bib17","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1073\/pnas.0901229106","article-title":"Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta","volume":"106","author":"Pigino","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"A\u03b2 oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J Neurosci"},{"issue":"5","key":"10.1007\/s13311-023-01405-0_bib19","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1046\/j.1471-4159.2000.0751977.x","article-title":"Reversible inactivation of superoxide-sensitive aconitase in A\u03b21-42-treated neuronal cell lines","volume":"75","author":"Longo","year":"2000","journal-title":"J Neurochem"},{"issue":"7","key":"10.1007\/s13311-023-01405-0_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/jnr.22640","article-title":"Intraneuronal amyloid \u03b2 oligomers cause cell death via endoplasmic reticulum stress, endosomal\/lysosomal leakage, and mitochondrial dysfunction in vivo","volume":"89","author":"Umeda","year":"2011","journal-title":"J Neurosci Res"},{"issue":"28","key":"10.1007\/s13311-023-01405-0_bib21","doi-asserted-by":"crossref","first-page":"18742","DOI":"10.1074\/jbc.M109.011015","article-title":"Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric A\u03b2","volume":"284","author":"Zhao","year":"2009","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0006-8993(97)01318-8","article-title":"Amyloid-\u03b2 peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release","volume":"785","author":"Hu","year":"1998","journal-title":"Brain Res"},{"issue":"6","key":"10.1007\/s13311-023-01405-0_bib23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/j.1471-4159.2006.04015.x","article-title":"Toxicity mediated by soluble oligomers of \u03b2-amyloid (1\u201342) on cholinergic SN56. B5. G4 cells","volume":"98","author":"Heinitz","year":"2006","journal-title":"J Neurochem"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11064-011-0592-1","article-title":"BDNF-, IGF-1-and GDNF-secreting human neural progenitor cells rescue amyloid \u03b2-induced toxicity in cultured rat septal neurons","volume":"37","author":"Kitiyanant","year":"2012","journal-title":"Neurochem Res"},{"issue":"5","key":"10.1007\/s13311-023-01405-0_bib25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/acel.12634","article-title":"Epigenetic regulation by G9a\/GLP complex ameliorates amyloid-beta 1\u201342 induced deficits in long-term plasticity and synaptic tagging\/capture in hippocampal pyramidal neurons","volume":"16","author":"Sharma","year":"2017","journal-title":"Aging Cell"},{"issue":"43","key":"10.1007\/s13311-023-01405-0_bib26","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1523\/JNEUROSCI.2441-08.2008","article-title":"A\u03b2 oligomers induce neuronal cell cycle events in Alzheimer's disease","volume":"28","author":"Varvel","year":"2008","journal-title":"J Neurosci"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1096\/fj.01-0987fje","article-title":"Selective neuronal degeneration induced by soluble oligomeric amyloid beta-protein","volume":"17","author":"Kim","year":"2003","journal-title":"FASEB J"},{"issue":"11","key":"10.1007\/s13311-023-01405-0_bib28","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u03b21\u201342 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10.1007\/s13311-023-01405-0_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jalz.2016.03.011","article-title":"Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint","volume":"12","author":"Rudinskiy","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"28","key":"10.1007\/s13311-023-01405-0_bib30","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/bi500587p","article-title":"Role of the fast kinetics of pyroglutamate-modified amyloid-\u03b2 oligomers in membrane binding and membrane permeability","volume":"53","author":"Lee","year":"2014","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-023-01405-0_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biocel.2016.08.037","article-title":"A critical concentration of N-terminal pyroglutamylated amyloid beta drives the misfolding of Ab1-42 into more toxic aggregates","volume":"79","author":"Galante","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"issue":"10","key":"10.1007\/s13311-023-01405-0_bib32","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1089\/ars.2010.3208","article-title":"Reactive oxygen species in the regulation of synaptic plasticity and memory","volume":"14","author":"Massaad","year":"2011","journal-title":"Antioxid Redox Signal"},{"issue":"14","key":"10.1007\/s13311-023-01405-0_bib33","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1212\/WNL.0000000000007248","article-title":"ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes","volume":"92","author":"Soldan","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-023-01405-0_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical alzheimer disease: a longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-2008-15404","article-title":"Anti-amyloid-\u03b2 immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials","volume":"15","author":"Wilcock","year":"2008","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-\u03b2 immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-Abeta(40) vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh((R)) amyloid beta peptide vaccine for mild Alzheimer's disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7","key":"10.1007\/s13311-023-01405-0_bib41","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/brain\/awab129","article-title":"Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys","volume":"144","author":"Patel","year":"2021","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01405-0_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104823","article-title":"Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials","volume":"139","author":"Petrushina","year":"2020","journal-title":"Neurobiol Dis"},{"issue":"35","key":"10.1007\/s13311-023-01405-0_bib43","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.1073\/pnas.1001740107","article-title":"Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering","volume":"107","author":"Sandberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-1-24","article-title":"Passive immunotherapy against A\u03b2 in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage","volume":"1","author":"Wilcock","year":"2004","journal-title":"J Neuroinflammation"},{"issue":"27","key":"10.1007\/s13311-023-01405-0_bib45","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","article-title":"Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition","volume":"24","author":"Wilcock","year":"2004","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-023-01405-0_bib46","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1023\/A:1023203122036","article-title":"Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice","volume":"28","author":"Lemere","year":"2003","journal-title":"Neurochem Res"},{"issue":"26","key":"10.1007\/s13311-023-01405-0_bib47","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1523\/JNEUROSCI.0664-05.2005","article-title":"Treatment with an amyloid-\u03b2 antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease","volume":"25","author":"Hartman","year":"2005","journal-title":"J Neurosci"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib48","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1073\/pnas.0436286100","article-title":"Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology","volume":"100","author":"Bard","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5597","key":"10.1007\/s13311-023-01405-0_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-A\u03b2 immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science"},{"issue":"15","key":"10.1007\/s13311-023-01405-0_bib50","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-023-01405-0_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt261","article-title":"Crystal structure reveals conservation of amyloid-\u03b2 conformation recognized by 3D6 following humanization to bapineuzumab","volume":"6","author":"Feinberg","year":"2014","journal-title":"Alzheimer's Research & Therapy"},{"issue":"Suppl 1","key":"10.1007\/s13311-023-01405-0_bib53","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1007\/s13311-023-01405-0_bib54","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"issue":"47","key":"10.1007\/s13311-023-01405-0_bib55","doi-asserted-by":"crossref","first-page":"12756","DOI":"10.1002\/anie.201406357","article-title":"A hexameric peptide barrel as building block of amyloid-\u03b2 protofibrils","volume":"53","author":"Lendel","year":"2014","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01405-0_bib58","author":"Hull"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1007\/s13311-023-01405-0_bib62","author":"Roche"},{"key":"10.1007\/s13311-023-01405-0_bib63","series-title":"Postgraduate open-label rollover study: evaluation of subcutaneous gantenerumab long-term safety, tolerability, and efficacy in participants with Alzheimer's disease (P6\u20133.002)","author":"Lane","year":"2022"},{"key":"10.1007\/s13311-023-01405-0_bib64","unstructured":"Bateman RJ, Smith J, Fox NC, Black SE, Shij Turner R, editors. The clinical development history of gantenerumab, a subcutaneous anti-A\u03b2 monoclonal antibody for early Alzheimer's disease: building on lessons from the past and paving a path for the future. San Diego: Presented at: Alzheimer's Association International Conference Annual Meeting; 2022."},{"key":"10.1007\/s13311-023-01405-0_bib65","series-title":"Characterization of the selective in vivo and in vitro binding properties of crenezumab: insights into crenezumab's unique mechanism of action (P6. 174)","author":"Meilandt","year":"2018"},{"issue":"21","key":"10.1007\/s13311-023-01405-0_bib66","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-023-01405-0_bib67","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-023-01405-0_bib68","article-title":"A public resource of baseline data from the Alzheimer's prevention initiative autosomal\u2010dominant Alzheimer's disease trial","author":"Reiman","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci Rep"},{"issue":"30","key":"10.1007\/s13311-023-01405-0_bib70","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1021\/jacs.6b05129","article-title":"Atomic resolution structure of monomorphic A\u03b242 amyloid fibrils","volume":"138","author":"Colvin","year":"2016","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1007\/s13311-023-01405-0_bib72","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"issue":"7618","key":"10.1007\/s13311-023-01405-0_bib73","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"14","key":"10.1007\/s13311-023-01405-0_bib74","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid \u03b2-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10.1007\/s13311-023-01405-0_bib75","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jnr.23510","article-title":"Small A\u03b21\u201342 oligomer-induced membrane depolarization of neuronal and microglial cells: Role of N-methyl-D-aspartate receptors","volume":"93","author":"Morkuniene","year":"2015","journal-title":"J Neurosci Res"},{"issue":"5","key":"10.1007\/s13311-023-01405-0_bib76","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","article-title":"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a\u03b2 oligomer bound to cellular prion protein","volume":"79","author":"Um","year":"2013","journal-title":"Neuron"},{"issue":"3","key":"10.1007\/s13311-023-01405-0_bib77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"issue":"11","key":"10.1007\/s13311-023-01405-0_bib78","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.2967\/jnumed.114.153494","article-title":"A semiautomated method for quantification of F 18 florbetapir PET images","volume":"56","author":"Joshi","year":"2015","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib79","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib81","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib82","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: appropriate use recommendations update","volume":"9","author":"Cummings","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1007\/s13311-023-01405-0_bib83","author":"Services CfMM"},{"key":"10.1007\/s13311-023-01405-0_bib84","article-title":"Aducanumab therapy to treat Alzheimer's disease: a narrative review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int J Alzheimers Dis"},{"issue":"45","key":"10.1007\/s13311-023-01405-0_bib85","doi-asserted-by":"crossref","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","article-title":"Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease","volume":"286","author":"Jawhar","year":"2011","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1007\/s13311-023-01405-0_bib86","article-title":"Full-length amyloid-beta (1\u201342 (43)) and amino-terminally modified and truncated amyloid-beta 42 (43) deposit in diffuse plaques","volume":"149","author":"Iwatsubo","year":"1996","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1007\/s13311-023-01405-0_bib87","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer's disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib88","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer's disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7","key":"10.1007\/s13311-023-01405-0_bib89","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMc2109455","article-title":"Donanemab in early Alzheimer's disease","volume":"385","author":"Espay","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1007\/s13311-023-01405-0_bib90","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-023-01405-0_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/alz.057492","article-title":"TRAILBLAZER-ALZ Study: dynamics of amyloid reduction after donanemab treatment","volume":"17","author":"Shcherbinin","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1007\/s13311-023-01405-0_bib92","series-title":"TRAILBLAZER-ALZ 2: a phase 3 study to assess safety and efficacy of donanemab in early symptomatic Alzheimer's disease (P18\u20133.005)","author":"Zimmer","year":"2022"},{"key":"10.1007\/s13311-023-01405-0_bib93","author":"Wall"},{"issue":"17 Supplement 2","key":"10.1007\/s13311-023-01405-0_bib94","article-title":"TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease","volume":"100","author":"Salloway","year":"2023","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib95","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib96","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/archneur.65.4.499","article-title":"Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease","volume":"65","author":"Basun","year":"2008","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1007\/s13311-023-01405-0_bib97","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u2018Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib98","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JAD-130029","article-title":"Specific uptake of an amyloid-\u03b2 protofibril-binding antibody-tracer in A\u03b2PP transgenic mouse brain","volume":"37","author":"Magnusson","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-018-1134-4","article-title":"The A\u03b2 protofibril selective antibody mAb158 prevents accumulation of A\u03b2 in astrocytes and rescues neurons from A\u03b2-induced cell death","volume":"15","author":"S\u00f6llvander","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib103","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.trci.2017.10.004","article-title":"Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5","volume":"3","author":"Papp","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14283\/jpad.2022.93","article-title":"ACU193, A monoclonal antibody that selectively binds soluble ass oligomers: development rationale, phase 1 trial design, and clinical development plan","volume":"10","author":"Siemers","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1007\/s13311-023-01405-0_bib105","series-title":"Trontinemab","author":"ALZFORUM","year":"2023"},{"key":"10.1007\/s13311-023-01405-0_bib106","unstructured":"Jin Y. Safety and amyloid plaque reduction effects of remternetug in patients with Alzheimer's disease: interim analysis from a phase 1 study. 2023 AD\/PD Conference; Gothernburg, Sweden; 2023."},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib107","article-title":"A call to address structural barriers to Hispanic\/Latino representation in clinical trials on Alzheimer's disease and related dementias: a micro-meso-macro perspective","volume":"9","author":"Aranda","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"11","key":"10.1007\/s13311-023-01405-0_bib108","doi-asserted-by":"crossref","first-page":"e1491","DOI":"10.1212\/WNL.0000000000011599","article-title":"Amyloid PET imaging in self-identified non-Hispanic Black participants of the anti-amyloid in asymptomatic Alzheimer's disease (A4) study","volume":"96","author":"Deters","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib109","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.25948","article-title":"Socioeconomic status mediates racial differences seen using the AT(N) framework","volume":"89","author":"Meeker","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-023-01405-0_bib110","author":"Brennan"},{"issue":"4","key":"10.1007\/s13311-023-01405-0_bib111","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/alz.12433","article-title":"Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1007\/s13311-023-01405-0_bib112","doi-asserted-by":"crossref","first-page":"219","DOI":"10.14283\/jpad.2020.46","article-title":"Recruitment into the Alzheimer prevention trials (APT) webstudy for a trial-ready cohort for preclinical and prodromal Alzheimer's disease (TRC-PAD)","volume":"7","author":"Walter","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"17","key":"10.1007\/s13311-023-01405-0_bib113","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-023-01405-0_bib114","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/d41573-022-00109-y","article-title":"Advancing innovative clinical trials to efficiently deliver medicines to patients","volume":"21","author":"Beckman","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"10.1007\/s13311-023-01405-0_bib115","article-title":"Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: why, how, and what we still need to know","volume":"13","author":"Erickson","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1007\/s13311-023-01405-0_bib116","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaneurol.2020.2734","article-title":"Short-term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment","volume":"77","author":"Grill","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1007\/s13311-023-01405-0_bib117","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1111\/jgs.17362","article-title":"Family members' perspectives on learning cognitively unimpaired older adults' amyloid-beta PET scan results","volume":"69","author":"Largent","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1007\/s13311-023-01405-0_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229137","article-title":"Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results","volume":"15","author":"Largent","year":"2020","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1007\/s13311-023-01405-0_bib119","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaneurol.2019.1879","article-title":"Associations of physical activity and beta-amyloid with longitudinal cognition and neurodegeneration in clinically normal older adults","volume":"76","author":"Rabin","year":"2019","journal-title":"JAMA Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01405-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01405-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01405-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:14:49Z","timestamp":1761808489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1878747923019049"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01405-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01405-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}